Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

2.27
+0.320016.41%
Post-market: 2.26-0.0100-0.44%18:01 EDT
Volume:113.03K
Turnover:242.08K
Market Cap:22.64M
PE:-0.52
High:2.30
Open:1.96
Low:1.96
Close:1.95
52wk High:19.35
52wk Low:1.70
Shares:9.97M
Float Shares:9.76M
Volume Ratio:1.35
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3427
EPS(LYR):-4.0377
ROE:-89.23%
ROA:-50.69%
PB:0.84
PE(LYR):-0.56

Loading ...

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

THOMSON REUTERS
·
Jun 13

Top Midday Decliners

MT Newswires Live
·
Jun 12

Atossa Therapeutics Launches $16.5 Million Registered Direct Offering

MT Newswires Live
·
Jun 11

Atossa Therapeutics issues Series A and B warrants for 1,363,638 shares in registered direct offering at $3.3 each

Reuters
·
Jun 11

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds

THOMSON REUTERS
·
Jun 11

Atossa says Phase 2 EVANGELINE trial tests (Z)-endoxifen plus goserelin in premenopausal ER+/HER2- breast cancer

Reuters
·
May 27

Atossa Therapeutics Announces Asco 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across Esr1 Mutations and Ongoing Evangeline Phase 2 Trial

THOMSON REUTERS
·
May 27

Atossa says (Z)-endoxifen Duchenne muscular dystrophy review accepted for publication

Reuters
·
May 21

Atossa Therapeutics Inc expected to post a loss of $1.03 a share - Earnings Preview

Reuters
·
May 08

Atossa Therapeutics Q1 net loss widens on higher legal and R&D expenses

Reuters
·
May 08

Atossa presents preclinical (Z)-endoxifen data in Duchenne muscular dystrophy mouse models

Reuters
·
May 08

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
May 08

Atossa Therapeutics Q1 Operating Expenses USD 9.87 Million

THOMSON REUTERS
·
May 08

Atossa Therapeutics Q1 FY26 net loss widens 61.07% to $9.6 million

Reuters
·
May 08

Atossa Therapeutics shareholders approve reverse stock split authorization

Reuters
·
May 08

Atossa says Phase 2 KARISMA trial shows Endoxifen cuts mammographic breast density 19.3%

Reuters
·
May 06

Atossa Therapeutics Announces Publication of Karisma Endoxifen Trial Demonstrating Significant Reduction in Mammographic Breast Density in Healthy Premenopausal Women

THOMSON REUTERS
·
May 06

BRIEF-Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen For Mccune-Albright Syndrome

Reuters
·
May 04

Atossa says FDA grants rare pediatric disease designation for (Z)-endoxifen in MAS

Reuters
·
May 04

Atossa Therapeutics - Co, Intas Pharmaceuticals, Jina Pharmaceuticals Agree Not to Challenge Specified Endoxifen-Related Patents - SEC Filing

THOMSON REUTERS
·
Apr 16